Medicamen Biotech Limited

NSE: MEDICAMEQ · Healthcare

Medicamen Biotech Limited Share Price & Analysis

245.65 -3.93%Updated 5 Jun 2026, 05:02 pm IST
LTP
245.65
-3.93%
Open
High
261.6
Low
243.35
Close
₹245.65
52W High
₹454
52W Low
₹217
Volume
47K
Lot Size
1
Sector
Healthcare
Market Cap
₹370 Cr
Face Value
₹10
Small Cap

Price Chart

Fundamentals

P/E
38.4
Sector P/E
48.9
P/B
1.21
EPS
₹7.06
ROE
3.95%
ROCE
5.43%
D/E Ratio
0.17
Div Yield
0.37%
Book Value
₹203
+

Strengths

  • Attractively valued vs sector (P/E 38.4x vs industry 48.9x)
  • Low debt relative to equity (D/E 0.2x)
  • Near 52-week low — potential value zone (₹217)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
1,783
₹4.3L Cr34.45.121620.50.07
DIVISLAB
Divi's Laboratories Limited
6,616
₹1.7L Cr66.110.4816.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
4,416
₹1.5L Cr66.417.8127.615.40.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,315
₹1.2L Cr59.512.6222.117.90.88
CIPLA
Cipla Limited
1,402
₹1.1L Cr27.33.2912.416.60.01
ZYDUSLIFE
Zydus Lifesciences Limited
1,091
₹1.1L Cr204.0521.221.20.38
DRREDDY
Dr. Reddy's Laboratories Limited
1,283
₹1.1L Cr25.42.8311.813.60.16

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

MEDICAMEQ · as of Mar 2026

Promoters43.16%0.17
FII0.12%0.06
DII0.69%0.18
Public55.99%0.05
Govt0.06%
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters43.21%43.21%42.99%42.99%42.99%43.16%
FII0.22%0.12%0.06%0.06%0.06%0.12%
DII0.67%0.99%1.17%1.17%0.87%0.69%
Public55.90%55.69%55.78%55.79%56.04%55.99%
Govt0.06%0.06%

Corporate Events

To consider and approve the financial results for the period ended March 31, 2026 and dividend

Dividend26 May 2026

Dividend - Re 1 Per Share

Dividend18 Sept 2025

Annual General Meeting/Dividend - Re 1 Per Share

Dividend18 Sept 2024

Annual General Meeting/Dividend - Re 1 Per Share

Dividend19 Sept 2023

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹46.91 Cr
▼0.6%
₹47.17 Cr
▲9.6%
₹43.04 Cr
▲45.4%
₹29.61 Cr
▼34.4%
₹45.14 Cr
▲0.9%
₹44.74 Cr
▲3.9%
₹43.05 Cr
▼9.0%
₹47.32 Cr
Op. Profit
₹4.38 Cr
▼15.1%
₹5.16 Cr
▲11.9%
₹4.61 Cr
▲386.3%
₹-1.61 Cr
▼124.0%
₹6.71 Cr
▲26.4%
₹5.31 Cr
▲53.9%
₹3.45 Cr
▼40.0%
₹5.75 Cr
OPM
9.3%
▼14.6%
10.9%
▲2.1%
10.7%
▲296.9%
-5.4%
▼136.6%
14.9%
▲25.2%
11.9%
▲48.2%
8.0%
▼34.1%
12.2%
Net Profit
₹1.64 Cr
▼22.6%
₹2.12 Cr
▲32.5%
₹1.6 Cr
▼14.4%
₹1.87 Cr
▼36.0%
₹2.92 Cr
▲220.9%
₹0.91 Cr
▲13.7%
₹0.8 Cr
▼60.8%
₹2.04 Cr
EPS (₹)
1.61
▼18.3%
1.97
▲23.9%
1.59
▼16.3%
1.9
▼30.4%
2.73
▲137.4%
1.15
▲8.5%
1.06
▼36.9%
1.68

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Revenue
₹198 Cr
▲21.5%
₹163 Cr
▼8.9%
₹179 Cr
▲27.0%
₹141 Cr
▲22.6%
₹115 Cr
▲1.8%
₹113 Cr
▼9.6%
₹125 Cr
▲1.6%
₹123 Cr
Expenses
₹178 Cr
▲20.3%
₹148 Cr
▼5.1%
₹156 Cr
▲33.3%
₹117 Cr
▲28.6%
₹91 Cr
▼2.2%
₹93 Cr
▼12.3%
₹106 Cr
▲1.0%
₹105 Cr
Op. Profit
₹20 Cr
▲42.9%
₹14 Cr
▼41.7%
₹24 Cr
▲0.0%
₹24 Cr
▲0.0%
₹24 Cr
▲20.0%
₹20 Cr
▲0.0%
₹20 Cr
▲17.6%
₹17 Cr
OPM
10.0%
▲11.1%
9.0%
▼30.8%
13.0%
▼23.5%
17.0%
▼19.0%
21.0%
▲23.5%
17.0%
▲6.3%
16.0%
▲14.3%
14.0%
Other Income
₹3 Cr
▼50.0%
₹6 Cr
▲200.0%
₹2 Cr
▲0.0%
₹2 Cr
▲0.0%
₹2 Cr
▲100.0%
₹1 Cr
▼50.0%
₹2 Cr
▼50.0%
₹4 Cr
Interest
₹4 Cr
▲0.0%
₹4 Cr
▼33.3%
₹6 Cr
▲100.0%
₹3 Cr
▲50.0%
₹2 Cr
▲0.0%
₹2 Cr
▲100.0%
₹1 Cr
▲0.0%
₹1 Cr
Depreciation
₹7 Cr
▲0.0%
₹7 Cr
▲0.0%
₹7 Cr
▲16.7%
₹6 Cr
▲0.0%
₹6 Cr
▲100.0%
₹3 Cr
▲50.0%
₹2 Cr
▲0.0%
₹2 Cr
PBT
₹12 Cr
▲20.0%
₹10 Cr
▼23.1%
₹13 Cr
▼23.5%
₹17 Cr
▼5.6%
₹18 Cr
▲12.5%
₹16 Cr
▼11.1%
₹18 Cr
▲0.0%
₹18 Cr
Tax %
18.0%
▼47.1%
34.0%
▲25.9%
27.0%
▲92.9%
14.0%
▼22.2%
18.0%
▼30.8%
26.0%
▲0.0%
26.0%
▼16.1%
31.0%
Net Profit
₹10 Cr
▲42.9%
₹7 Cr
▼22.2%
₹9 Cr
▼40.0%
₹15 Cr
▲0.0%
₹15 Cr
▲25.0%
₹12 Cr
▼7.7%
₹13 Cr
▲8.3%
₹12 Cr
EPS (₹)
7.11
▲27.2%
5.59
▼35.0%
8.6
▼26.7%
11.73
▼3.9%
12.2
▲22.9%
9.93
▼8.7%
10.88
▲5.8%
10.28
Div Payout
14.0%
▼22.2%
18.0%
▲50.0%
12.0%
▲33.3%
9.0%
▲12.5%
8.0%
▼20.0%
10.0%
▲100.0%
5.0%
▼50.0%
10.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Sep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Liabilities
Equity Capital
₹14 Cr
▲0.0%
₹14 Cr
▲7.7%
₹13 Cr
▲0.0%
₹13 Cr
▲0.0%
₹13 Cr
▲8.3%
₹12 Cr
▲0.0%
₹12 Cr
▲0.0%
₹12 Cr
▲0.0%
₹12 Cr
Reserves
₹262 Cr
▲0.0%
₹262 Cr
▲31.0%
₹200 Cr
▲3.1%
₹194 Cr
▲7.2%
₹181 Cr
▲35.1%
₹134 Cr
▲10.7%
₹121 Cr
▲11.0%
₹109 Cr
▲45.3%
₹75 Cr
Borrowings
₹48 Cr
▲23.1%
₹39 Cr
▲14.7%
₹34 Cr
▲9.7%
₹31 Cr
▲19.2%
₹26 Cr
▲0.0%
₹26 Cr
▲36.8%
₹19 Cr
▲72.7%
₹11 Cr
▼8.3%
₹12 Cr
Other Liabilities
₹49 Cr
▼7.5%
₹53 Cr
▲6.0%
₹50 Cr
▼10.7%
₹56 Cr
▼5.1%
₹59 Cr
▲11.3%
₹53 Cr
▲26.2%
₹42 Cr
▼14.3%
₹49 Cr
▲28.9%
₹38 Cr
Total Liabilities
₹372 Cr
▲1.4%
₹367 Cr
▲23.6%
₹297 Cr
▲0.7%
₹295 Cr
▲5.7%
₹279 Cr
▲23.5%
₹226 Cr
▲16.5%
₹194 Cr
▲7.2%
₹181 Cr
▲32.1%
₹137 Cr
Assets
Fixed Assets
₹85 Cr
▼1.2%
₹86 Cr
▼1.1%
₹87 Cr
▼5.4%
₹92 Cr
▼1.1%
₹93 Cr
▲1.1%
₹92 Cr
▲2.2%
₹90 Cr
▲164.7%
₹34 Cr
▲41.7%
₹24 Cr
CWIP
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
▼100.0%
₹40 Cr
▲166.7%
₹15 Cr
Investments
₹0 Cr
▼100.0%
₹8 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
Other Assets
₹287 Cr
▲5.1%
₹273 Cr
▲30.0%
₹210 Cr
▲3.4%
₹203 Cr
▲9.1%
₹186 Cr
▲39.8%
₹133 Cr
▲27.9%
₹104 Cr
▼2.8%
₹107 Cr
▲10.3%
₹97 Cr
Total Assets
₹372 Cr
▲1.4%
₹367 Cr
▲23.6%
₹297 Cr
▲0.7%
₹295 Cr
▲5.7%
₹279 Cr
▲23.5%
₹226 Cr
▲16.5%
₹194 Cr
▲7.2%
₹181 Cr
▲32.1%
₹137 Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Operating CF
₹-8 Cr
▼14.3%
₹-7 Cr
▼16.7%
₹-6 Cr
▼250.0%
₹4 Cr
▼69.2%
₹13 Cr
▲0.0%
₹13 Cr
▲225.0%
₹4 Cr
Investing CF
₹-1 Cr
▲83.3%
₹-6 Cr
▲0.0%
₹-6 Cr
▲25.0%
₹-8 Cr
▲55.6%
₹-18 Cr
▲51.4%
₹-37 Cr
▼146.7%
₹-15 Cr
Financing CF
₹-1 Cr
▼116.7%
₹6 Cr
▼79.3%
₹29 Cr
▲625.0%
₹4 Cr
▼33.3%
₹6 Cr
▼68.4%
₹19 Cr
▲575.0%
₹-4 Cr
Net Cash Flow
₹-11 Cr
▼83.3%
₹-6 Cr
▼135.3%
₹17 Cr
₹0 Cr
▼100.0%
₹1 Cr
▲120.0%
₹-5 Cr
▲64.3%
₹-14 Cr
Free Cash Flow
₹-10 Cr
▲23.1%
₹-13 Cr
▲0.0%
₹-13 Cr
▼225.0%
₹-4 Cr
▲20.0%
₹-5 Cr
▲80.0%
₹-25 Cr
▼127.3%
₹-11 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Debtor Days
151d
▼2.6%
155d
▲38.4%
112d
▼33.7%
169d
▼15.5%
200d
▲17.6%
170d
▲17.2%
145d
▲12.4%
129d
Inventory Days
251d
▼6.3%
268d
▲14.5%
234d
▲2.6%
228d
▲21.3%
188d
▲596.3%
27d
▼65.4%
78d
▲16.4%
67d
Days Payable
144d
▼21.7%
184d
▲19.5%
154d
▼36.1%
241d
▼20.2%
302d
▲78.7%
169d
▼2.3%
173d
▲29.1%
134d
Cash Conv. Cycle
259d
▲8.4%
239d
▲23.8%
193d
▲23.7%
156d
▲81.4%
86d
▲207.1%
28d
▼45.1%
51d
▼17.7%
62d
Working Capital Days
193d
▲3.8%
186d
▲51.2%
123d
▼21.2%
156d
▲6.1%
147d
▲16.7%
126d
▼3.1%
130d
▲12.1%
116d
ROCE
5.0%
▼16.7%
6.0%
▼25.0%
8.0%
▼20.0%
10.0%
▼16.7%
12.0%
▼7.7%
13.0%
▼18.8%
16.0%

Source: Screener.in · Lower days = better efficiency

Frequently Asked Questions

What is Medicamen Biotech Limited share price today?
Medicamen Biotech Limited (MEDICAMEQ) is currently trading at ₹245.65 on NSE, down 3.93% as of the last market session. Prices update daily after market close on MarketNetra.
Is Medicamen Biotech Limited available in F&O (Futures & Options)?
Yes, Medicamen Biotech Limited (MEDICAMEQ) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Medicamen Biotech Limited 52-week high and low?
Medicamen Biotech Limited's 52-week high is ₹454 and the 52-week low is ₹217. The current price of ₹245.65 is 45.9% below the 52W high.
What is Medicamen Biotech Limited P/E ratio?
Medicamen Biotech Limited's current P/E ratio is 38.4. This indicates the market is paying ₹38.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Medicamen Biotech Limited options?
Medicamen Biotech Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade MEDICAMEQ options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.